Skip to Main Content

By the end of this week, Moderna Therapeutics is likely to pull off the biggest initial public offering in biotech history, a $500 million fundraise with sweeping implications for the company, its innovative science, and the drug business as a whole.

Before Moderna — and its audacious plan to upend the industry — tests Wall Street’s appetite, here’s a guide to the outstanding questions pegged to biotech’s most scrutinized unicorn.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.